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Abstract
Background: Extraosseous plasmacytoma, so called extramedullary plasmacytoma (EMP) is relatively rare in China.
The aim was investigate the clinicopathologic features of EMP and the role of Immunophenotype and genotype
detection in diagnosis of EMP.
Methods: Thirty-two cases of EMP were investigated retrospectively by histopathology, immunophenotype,
genotype and survival analysis.
Results: Clinically, the mean age of the patients was 53.4. Most of the patients received no treatment after the
diagnosis was established, and the prognosis was relatively poor. Histologically, in 40% of the cases, the neoplastic
cells were grade II or III. The neoplastic cells expressed one or more PC associated antigens. The
immunophenotype of EMP and inflammation of sinonasal regions with numerous PC infiltrations were compared
and showed some difference in expression of CD45, CD27, CD44v6 and Bcl-2 as well. Ig light chain restriction was
detected in 87.5% of the cases.
Conclusions: we described 32 Chinese cases of EMP, compare with that reported in the literature, some
differences are presented, including higher percentage of grade II and III cases, clinically inconsistent treatment and
management as well as poor outcome of the disease.
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Background
Extraosseous plasmacytomas, so called extramedullary
plasmacytomas (EMP) is defined by the updated WHO
classification (2008) as localized plasma cell neoplasms
that arise in tissues other than bone [1]. EMP is a rare
tumor and accounts for 3~5% of all plasma cell neo-
plasm. Approximately 80% of them occur in the upper
aerodigestive tract. EMP has also been noted to arise in
other anatomic sites, including the gastrointestinal tract,
lymph node, bladder, CNS, breast, thyroid, testis, parotid
and skin [1,2]. There were a few reports of the tumor in
large numbers in literatures, and most of those studies
mainly focused on clinical features and outcome analysis
of the tumor as well [3,4]. Dores GM et al [5] reviewed
and analyzed the incidence and survival for plasmacy-
toma of bone, EMP and multiple myeloma reported in
the United States in period of 1992-2004. There were
1543 cases of plasmacytomas, and EMP occupied 30.7%
(474/1543). In all 474 cases of EMP, most patients were
white males with advanced age, only 41 of them were
A s i a n s .F u r t h e r m o r e ,t h e r ei ss t i l ln or e p o r to fE M P
coming from Mainland China in literature review now.
In the period of January 1990 to February 2007, the
total number of plasma cell neoplasms diagnosed in
West China Hospital of Sichuan University (Chengdu,
China) was 279, accounting for 13.97%(39/279) of all
plasma cell neoplasms diagnosed in this period. In the
current study, 32 cases of EMP were studied retrospec-
tively for the clinicopathologic and immunophenotypic
features of the tumor.
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Patient selection
Thirty nine patients with EMP were collected from the
Pathology Department, West-China Hospital of Sichuan
University in the period of January 1990 to February
2 0 0 7 .S e v e no ft h e mw e r ee x c l u d e df r o mt h es t u d y
because of insufficient materials or problems of the clin-
ical data. The remaining 32 cases were included in this
study. Histological diagnosis of the tumors was based on
WHO classification of the tumors of haematopoietic
and lymphoid tissues (2008)[1] and HIV infection was
not detected in all patients. Consistent methods used
were as follows: (1) examination of histological features
on slides of biopsies; (2) immunophenotype analysis on
paraffin embedded tissue sections including B and T-cell
differentiation antigens, universal plasma cell markers
and some of related markers, as well as proliferation
index; (3) Immunoglobulin (Ig) heavy chain gene (IGH)
and light chain gene (IGK and IGL) rearrangement ana-
lysis by PCR. All cases selected fever the recommended
diagnostic criteria for solitary EMP compiled by Soutar
R, et al [6], they are as follows: (1) single extramedullary
mass of clonal plasma cells; (2) histologically normal
marrow aspirate and trephine; (3) normal results in ske-
letal survey, including radiology of long bone; (4) no
anemia, hypercalcaemia or renal impairment due to
plasma cell dyscrasia; (5) absent or low serum or urinary
level of monoclonal immunoglobulin. The clinical fea-
tures of these 32 patients, including age, gender, clinical
course and follow-up data were compiled. In addition,
21 cases of solitary plasmacytoma of bone (SPB) and 12
cases of inflammatory lesions of aerodigestive tracts
with numerous plasma cells were used as a control for
immunohistochemistry and analysis.
Histopathologic review
Routine H&E stained sections were used to assess the
histopathologic features. The cases were graded accord-
ing to the histological grading criteria described by Bartl
et al [7] (1987). In addition, coagulation necrosis, amy-
loid deposition, blood cell lake as well as growth pattern
of “starry sky” were also observed in morphologic review
of the tumors. The mitotic index was estimated by
counting the number of mitotic figures in 10 randomly
selected high power fields(HPF) at 40 × 10 magnifica-
tions on a Leica 020-518.500 DM/LS microscope (Leica
Microsystems Holding GmbH, Wetzlar, Germany).
Immunohistochemistry analysis
The antibodies used include CD19 (LE-CD19, Dako,
Denmark), CD20 (L26, Dako, Denmark), CD27 (137B4,
Thermo, USA), CD38 (AT1, NeoMarker, USA), CD44v3
(VEF-327v3, NeoMarker, USA), CD44v6 (2F10,
NeoMarker, USA), CD45 (PD7/26, Dako, Denmark),
CD56 (123, C3, Zymed, CA), CD79a (JCB117, Dako,
Denmark), CD117 (polyclonal, Dako, Denmark), CD138
(MI15, GeneTech, USA), PC (VS38C, Dako, Denmark),
EMA (E29, Dako, Denmark), Bcl-2 (124, Dako, Den-
mark), CyclinD1 (SP4, Thermo, USA), kappa and
lambda immunoglobulin (Ig) light chains (polyclonal,
NeoMarker, USA) and Ki-67 (MIB-1, NeoMarker, USA).
Four-micrometer thick sections were cut and deparaffi-
nized in xylene and hydrated in a graded series of etha-
n o l .T h es l i d e sw e r et h e np r e t r e a t e db yp r e s s u r e -
cooking in citric acid buffer (10 mM, pH 7.4) for 3 min-
utes before staining for CD19, CD20, CD38, CD44v3,
CD44v6, CD45, CD56, CD79a,P C ,E M A ,B c l - 2 ,i n
EDTA (1 mM, pH 9.0) for 8 minutes before staining for
CD27, CD138, CyclinD1 and Ki-67 and in Trypsin (pH
7.8) for 10 minutes before staining for Ig and Igl light
chains. Envision method was used for Immunohisto-
chemical staining for CD19, CD20, CD45, CD79a,
CD117, PC, EMA, Bcl-2, CyclinD1, Ig,I g l, and Elivi-
sion method was used for CD27, CD38, CD56, CD138,
CD44v3, CD44v6, Ki-67. DAB was used as a substrate
and the positive signal was dark brown in color.
DNA extraction and polymerase chain reaction
Genomic DNA from paraffin-imbedded tissue samples
was extracted by phenol-chloroform procedures. Suc-
cessful DNA extraction was confirmed by amplification
of 110 bp fragment of b-globin. Both universal IGH
(FR3A/LJH/VLJH) primers and the BIOMED-2 PCR
multiplex tubes were used for IGK and IGL rearrange-
ment analysis. For universal IGH (FR3A/LJH/VLJH)
detection, the major procedure was as follows: 1 μLo f
each primer at 25 μmol/L (Takara, Tokyo, Japan) were
used in 25-μL reaction mixture. The PCR mixture
(Takara, Tokyo, Japan) contained 2.5 μLo f1 0×P C R
buffer, 1.5 μLo fM g C l 22 5m m o l / L ,2μlo fd N T P2 . 5
mmol/L of, 1.25 U of Taq DNA polymerase and 1 μg
template DNA. Five microliters of PCR products was
electrophoresed in 1.5% agarose gels (110 V, 30 min).
Gels were stained with Goldview (Saibaisheng, China)
and examined with ultraviolet light using the Image
Acquisition and Analysis Software (Bio-Rad Labora-
tories, Herchles, CA). The BIOMED-2 PCR multiplex
tubes (IgH, IGK and IGL) detection was according to
the procedure of van Dongen et al [8].
Survival and statistical analysis
Follow-up data were available in 15 of the 32 patients
(46.9%). The overall survival time was plotted using the
Kaplan-Meier (SPSS 13.0; SPSS, Chicago, IL). For com-
parison of the various parameters of immunohistochem-
istry of EMP, SPB and inflammatory lesions of nasal and
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tions, c2 test was used. A p value of 0.05 was considered
significant.
Results
Clinical manifestations
The clinical features of the patients are summarized in
Table 1 and the manifestations in Table 2. The age of
the patients ranged from 30 to 85 years and the mean
age at diagnosis was 53.4 years. The male to female
ratio was 2.2:1. The period to onset of the tumor was
14.1 months. The upper aerodigestive tract and tonsil
were the most common sites of the disease, accounting
for 72% of the cases, followed by skin (6 cases, 18.8%),
gum, lung and testis (1case each). The patients displayed
a solitary polyp like lesion in the upper aerodigestive
tract (Figure 1) or nodule in subcutaneous or other
solid organs. The size of the tumor ranged from 0.5 ×
0.5 × 0.5 cm to 20.0 × 15.0 × 10.0 cm. The manifesta-
tions are closely related to the anatomic sites involved,
e.g. in patients with nasal cavity or sinonasal lesions, the
symptoms include nasal obstruction, rhinorrhoea and
epistaxis. Laboratory examination did not show
increased white cell count or plasmacytosis in all 32
cases. Serum and urine protein electrophoresis and
immunofixation were performed in 21 and 8 patients,
respectively. Low serum level of M-components was
found in 2 of the 21 cases (9.5%), one of IgG type (21.4
g/L) and another of IgA type (4.36 g/L). whereas no M-
protein of urine was found in all 8 patients examined.
All patients received bone marrow aspiration or trephine
and skeletal survey by standard X-ray and computed
tomography (CT) or magnetic resonance imaging (MRI).
No multiple osteolytic lesions were identified except for
the solid mass in the involved regions. There was no
evidence of bone marrow involvement at the time of
diagnosis as well.
Histopathologic findings
The morphologic features of the cases are summarized
in Table 3. According to histological grading criteria
described by Bartl et al (1987), 18 of 32 cases (56.3%)
were classified as well differentiated (grade I), 10 cases
(31.3%) as moderately differentiated (grade II), and the
remaining 4 cases (12.4%) as poorly differentiated (grade
III). The neoplastic cells of grade I were similar to that
of normal plasma cells and mitotic figure was rare. In
contrast to the well differentiated EMP, the neoplastic
cells of grade III often showed plasmablastic morphol-
ogy exhibiting large nuclei with open chromatin and
prominent nucleoli, mitotic figures were easily seen and
tumor giant cells were also observed in 4 cases. Whereas
the neoplastic cells of grade II were less homogeneous,
and intermingled with normal looking plasma cells and
anaplastic cells. Dutcher’s bodies were seen in 4 cases
(12.5%). Coagulation necrosis was visible in 11 of 32
cases (34.4%). Amyloid deposition with granulomatous
reaction was found in 6 (18.8%). Blood cell lakes were
presented 12 cases (37.5%). In addition, a “Starry Sky”
pattern was observed in 3 cases (9.4%) (Figures 2 and 3).
Immunophenotype and genotype
The results of immunohistochemistry were summarized
in Table 4. The neoplastic cells were positive for CD138
(100%), CD38 (90.6%) and vs38c (95.5%). 11 cases
(34.4%) expressed CD45 antigen. Nearly 50% of the
cases, the tumor cells expressed CD79a. In two cases
some of tumor cells gave a positive reaction to CD20 or
CD19, respectively. Bcl-2 expression was found in 31
cases (96.9%). The tumor cells expressed CD56 and
Cyclin D1 protein in 6 cases each (18.8%). The expres-
sions of CD117, CD27 and EMA were 28.1%, 43.8% and
31.3%, respectively. 56.3% and 11.5% of the cases
expressed adhesion molecules of CD44v3 and CD44v6.
Ig light chain restriction was observed in 28 cases
(87.5%), including Ig restriction of 11 cases (34.4%)
and Igl of 17 cases (53.1%). Ki-67 index was increased
with the advanced histologic grading and ranged from 1
Table 1 Clinical features (n = 32)
Contents Patients
No./Total
number
Percentage
Sex
Male 22 62.5
Female 10 37.5
Age (years)
Range 30~85
Mean 53.4
Median 60
Sites
Upper areodigestive tract 21 65.6
Tonsil 2 6.3
skin 6 18.8
Gingiva 1 3.1
Lung 1 3.1
Testis 1 3.1
Auxiliary examination
Normal marrow aspirate 32 100
Normal results on skeletal survey 32 100
low serum level of M-
components
2/21 9.5
low urinary level of M-
components
0/8 0
Follow up (n = 15, month)
Dead 10/15 67 (6.6 m)
Alive with disease 3/15 20 (11.3 m)
Alive with recurrence 2/15 13 (24 m)
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EMP and inflammation of sinonasal regions with
numerous PC infiltrations were compared and showed
some difference in expression of CD45, CD27, CD44v6
and Bcl-2 and listed in Table 5. The difference in
expression of CD56, CD27, CD44v6 and EMA between
EMP and SPB were compared and showed in Table 6.
Antigen receptor gene analysis was performed in 24
cases. Immunoglobulin heavy and light chain gene were
clonally rearranged in sixteen of 24 cases (66.7%),
including IGH of 9 cases (37.5%), IGK of 12 cases (50%)
as well as IGL of 6 cases(25%).
Treatment, follow-up, and survival analysis
Because most patients were treated in Outpatient
Department of our hospital, the related data were una-
vailable or incomplete. Nevertheless, all patients received
surgery for establishment of the diagnosis and/or initial
treatment. Three patients (case 7, 19 and 32) received
radiotherapy following surgery, and the total does was
45~65Gy. In addition, one patient (case 7) also received
chemotherapy and the regimen was unknown.
Follow-up data were available for 13 patients (40.6%),
and the other 2 died patients (6.25%), in whom the exact
date and cause of death were all unknown at all. For the
Table 2 Clinicopathologic features and follow-up data
No. Age
(years)
Sex Sites Size
(cm)
Grading* therapy Follow-up
(months)
1 61 M NC 1 × 1 × 1 II S Lost
2 63 M NC and PNS 8 × 5 × 1 II S Lost
3 32 M NC and PNS 2 × 2 × 2 II S Lost
4 60 F Lung 4.3 × 3.5 × 1.5 I S Lost
5 47 M NC 0.5 × 0.5 × 0.5 I S ANED 123
6 53 M NC 1 × 1 × 1 I S Lost
7 55 F NC and PNS 5 × 3 ×1.5 I S+RT+C AWD 110
8 62 F Chest wall 11 × 1 0 I S Lost
9 63 M Tonsil 3.5 × 3 × 2 I S AWD 97
10 54 M NP 2 × 2 × 1 I S Lost
11 46 M Occiput 8 × 6 × 3 I S Lost
12 49 F NC 1.5 × 1 ×0.2 II S Lost
13 48 M NC 1.5 × 1 ×0.6 III S Died ?
14 58 M NC and PNS 6 × 4 × 1 III S ANED 81
15 32 M PNS 4.5 × 4 × 1.5 II S AWD 92
16 47 M trunk (back) 20 × 1 5 × 1 0 I S AWD 75
17 34 M NC and PNS 3 × 3 ×1 I S Lost
18 50 F NC 1 × 1 ×1 III S Lost
19 66 F NP 0.5 × 0.5 × 0.5 I S+RT ANED 65
20 77 M Cervical 2 × 1.5 × 0.8 I S Lost
21 35 M NC and PNS 6 × 5 × 3 II S Lost
22 47 M NC and PNS 3 × 3 × 2 II S DOD 17
23 55 M PNS 2 × 1.6 × 0.6 I S Died ?
24 63 M PNS 3 × 1.6 × 0.8 I S DOD 51
25 67 F gum 1.5 × 1.2 × 1 II S Lost
26 65 M cervicum 1 × 1 ×0.7 I S Lost
27 85 F forehead 2 × 1.4 × 1 I S DOD 11
28 56 M PNS 6 × 5 × 1 III S DOD 228
29 30 M testis 3.5 × 3 × 2 II S Lost
30 56 M NC 1 × 1 × 0.3 I S ANED 17
31 35 F tonsil 1 × 1 × 1 I S AWD 6
32 59 F PNS 5 × 4 × 3 II S+RT Lost
M = male; F = female;
*Grading, according to Bartl et al. RT = Radiotherapy;
AWD = alive with disease; DOD = died of disease;
ANED = alive with no evidence of disease; NC = nasal cavity;
S = surgery; NP = nasopharynx;
C = chemotherapy; PNS = paranasal sinus.
R = relapse
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228 months, average of 74.8 months. 9 were grade I cases,
and 4 were grade II and III. The overall survival time and
the average survival time were 51 and 78.1 months,
respectively. At the last follow-up, 4 patients died of the
disease; 5 patients were alive with disease; and the remain-
ing 4 patients were alive with complete remission (CR) as
well. Furthermore, in 3 of the four patients living with CR,
the size of the tumors was smaller (0.5 to 1 cm in dia-
meter) and the histologic grading was lower (grading I) as
well. No patient developed MM in process of the disease.
Discussion
EMP is relatively rare, in our hospital, the total number
of EMP diagnosed in period of 1990 and 2007 was 39,
accounting for 13.97% (39/279) of all plasma cell neo-
plasms and 0.46% (39/8481) of all lymphoid neoplasms
diagnosed during this period. Recently, Dores GM et al
[5] reviewed plasma cell neoplasms reported in the lit-
erature in period of 1992-2004, and analyzed the inci-
dence and survival for plasmacytoma of bone, EMP and
multiple myeloma (MM) reported in the United States
in this period. There were 1543 cases of plasmacytomas,
and EMP occupied 30.7% (474/1543). In all 474 cases of
EMP, most patients were white males with advanced
age, only 41 of them were Asians. To date, the largest
number of EMP (68 cases) was reported from Canada
by Bachar et al [3] in 2008. The clinical features in cur-
rent group of the cases are summarized as follows: (1)
the patients were old, with a mean age of 60 years and
male predominant; (2) in about 72% of the patients, the
tumors were located in the midfacial region, and a high
percentage of skin involvement was noticed; (3) most
patients received no treatment, and the prognosis was
relatively poor; (4) no development of MM was found.
As a result, the general clinical manifestations of the
patients are almost same as that reported in the litera-
tures, including the age, gender, anatomic sites of the
tumor and so on [2-4,6,9,10]. Talking about the treat-
ment of the tumor, because the upper respiratory tract
is most commonly involved, it is almost impossible to
remove the tumor completely by operation, so that
radiotherapy is often the first choices. No does-response
relationship was observed now. The optimal radiation
Figure 1 A mass of EMP in oral cavity (case 31).
Table 3 Morphologic features (n = 32)
Morphology Number Percentage
Tumor cell differentiation
Well (Grade I) 18 56.3
Moderate (Grade II) 10 31.3
Poor (Grade III) 4 12.4
Tumor giant cells 10 31.3
Dutcher’s body 4 12.5
Necrosis 11 34.4
Amyloid deposition 6 18.8
Blood cell lake 12 37.5
“Starry Sky” pattern 3 9.4
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than 5 cm in diameter, a higher does of radiation may
be necessary for an effective treatment [6]. In the
patients received radiotherapy, local recurrence rate of
the tumor is usually less than 5%. Secondly, for the
EMP of other anatomic sites, complete surgical removal
should be considered if feasible. In addition, no recom-
mendation for adjuvant radiotherapy can be made for
patients who have undergone complete surgical excision
with negative margins [6]. Bachar et al [3] reported 68
cases of solitary EMP of head and neck, the 5-year local
recurrence-free rate (LRFR) was 81%, regional recur-
rence at 5 year was 5%, MM developed in 23% of the
patients, and the 5-year survival rate was 76%. In cur-
rent study, because most of our patients did not receive
further treatment, after the diagnosis of EMP was estab-
lished, their prognosis were not as good as that reported
in the literature at all [5,6,11].
The histologic features of the cases in the current
study are summarized as follows: (1) the neoplastic cells
were moderately or poorly differentiated (grade II and
III) in 40% of cases; (2) Variety degree of coagulative
necrosis was observed in one third of the cases; (3)
Amyloid deposition with granulomatous reaction and
Dutcher’s bodies were seen in 18.8% and 12.5% of the
cases, respectively. Based on the report in literature,
Most of EMP are well differentiated, the neoplastic cells
are similar to normal plasma cells, especially the lesion
of the upper aerodigestive tracts, there are often inter-
mingled with variety of inflammatory cells, distinction
between non-specific inflammation and plasma cell neo-
plasm is always problematic, Ig light chain restriction
and Ig gene rearrangement analysis are useful in distin-
guishing non-neoplastic polyclonal proliferation from
neoplastic clonal proliferation of plasma cells. In addi-
tion, because the morphologic changes of EMP are
almost similar to those of extramedullary invasion of
well differentiated MM, the diagnosis of EMP must be
established on absolutely rule out the possibility of MM.
The major clinical features of MM include hypercalce-
mia, renal insufficiency, anemia, multiple osteolytic
lesions and so on. A constellation of clinical, laboratory,
radiological and pathologic findings play an important
role in diagnosis of MM as well. Sometimes, distinction
f r o mam a r g i n a lz o n el y m p h o m aw i t hm a r k e dp l a s m a
cell differentiation is also a problem, particularly in skin
and gastrointestinal tract, and may not be possible in
some instance [1]. In contrast to the reports in litera-
tures, higher percentage of grade II and III cases was
noticed in current study, The differential diagnosis
include the following neoplasms, such as large B-cell
lymphoma (LBCL), poorly differentiated carcinoma, mel-
anoma, as well as other types of sarcomas with features
of epithelial differentiation. Immunohistochemistry will
help a lot in distinction among those tumors. For LBCL,
the neoplastic cells usually give a positive reaction to B-
cell differentiation antigens, such as CD19, CD20,
CD79a, PAX5 and so on, and usually negative for
plasma cell markers of CD138 and CD38. Cytokeratins
of different molecular weights are the useful markers for
Figure 2 Histopathologic features of EMP. A. H&E stained section
showed tumor cells of Grade I (case 27). B. Tumor cells of Grade II
(case 22). C. Tumor cells of Grade III (case 28). D. Tumor cells
infiltrated in subdermis (case 1).
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times, the neoplastic cells of poorly differentiated squa-
mous cell carcinoma or adenocarcinoma, may also
express CD138 or PC, it is necessary to choose a penal
of antibodies in differentiation between carcinoma and
EMP. The neoplastic cells of melanoma usually express
HMB-45, MART-1 and S-100 protein, and it is easy to
distinguish melanoma from EMP.
The immunophenotypic features of the cases in this
study are summarized as follows: (1) the neoplastic cells
of all cases expressed one or more plasma cell asso-
ciated antigens; and CD138 and CD38 were better than
PC in both sensitivity and specificity as well; (2) some
difference of immunophenotypic expression in EMP,
SPB and inflammation of sinonasal regions with numer-
ous PC infiltrations were observed; (3) 87.5% of the
cases displayed Ig light chain restriction, with Igl type
predominant; (4) Ki-67 index was elevated with the
advanced histologic grading. In contrast to MM, there
are limited reports giving a special observation for the
immunophenotypic feature of plasmacytomas and their
significance in literatures.
CD45, a key regulator of antigen mediated signaling
and activation in lymphocytes, is present in early stages
of PCs development. Kumar S et al [12] reported a total
of 75 patients with untreated MM (29), relapsed MM
(17), smoldering MM (12), and monoclonal gammopa-
thy of undetermined significance (MGUS) (17), the pro-
portion of PCs expressing CD45 was higher among
those with early disease (MGUS or smoldering MM)
compared to those with advanced disease (new or
relapsed MM) (43 vs 22%; P¼0.005). Moreau P [13]
reported that patients with CD45 negative MM receiving
high-dose therapy have a shorter survival than those
Figure 3 Histopathologic features of EMP. A. Dutcher’s body (case 1). B. tumor giant cells (case 24). C. Amyloid deposition stained by congo
red (case 9). D. Amyloid deposition stained by congo red showed a characteristic “apple-green” birefringence under polarized light (case 9).
Table 4 Immunophenotype (n = 32)
Antibody Clonality +/Total number Percentage
CD45 PD7/26 11/32 34.4
CD20 L26 1/32 3.1
CD19 LE-CD19 1/32 3.1
CD79a JCB117 15/32 46.9
CD138 MI15 32/32 100
CD38 AT1 29/32 90.6
PC vs38c 23/24 95.8
CD56 123C3 6/32 18.8
*CD117 - 9/32 28.1
EMA E29 10/32 31.3
CD27 137B4 14/32 43.8
CD44v3 VEF-327v3 3/26 11.5
CD44v6 2F10 18/32 56.3
Bcl-2 124 31/32 96.9
CyclinD1 SP4 6/32 18.8
*Ig - 11/32 34.4
*Igl - 17/32 53.1
* Polyclonal antibody
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EMP gave a positive reaction to CD45, whereas in 12
cases of inflammation of aerodigestive tracts, the infil-
trated plasma cells were all positive for CD45.
Aberrant expression of CD56 is almost always
observed in MM and more than 70% cases of MM
express CD56 [14-16]. Few reports revealed that CD56
expressed in solitary plasmacytoma of bone (SPB) and
in 10% EMP cases [4,17] Kermer M et al [4] compared
the difference of Immunophenotype between EMP and
MM. the results showed that EMP was infrequent
expression of CD56, in contrast to both intra- and
Figure 4 Immunophenotype of EMP, Grade I (case 16). A. CD138. B. CD38. C. CD56. D. CD27. E. CD44v6. F. Ki67. G&H. Tumor cells showed
the restricted lamppa chain expression.
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tage of CD56 expression was slightly higher than that
reported in literature. We also observed CD56 expres-
sion in a group of inflammatory lesions of sinonasal
regions with numerous plasma cell infiltrations; no PC
gave a positive reaction to CD56 (the data did not show
in this paper). The results suggested that CD56 may be
used as a marker in differentiation between EMP and
MM.
CD27 is a member of the still growing TNF receptor
family [18,19] and is a marker of memory B cells, and
its interaction with its ligand, CD70, is very important
Figure 5 Immunophenotype of EMP, Grade III. A. CD138 (case 14). B. CD38 (case 18). C. CD56 (case 13). D. CD27 (case 28). E. CD44v6 (case
14). F. Ki67 (case 13). G&H. Tumor cells showed the restricted kappa chain expression (case 13).
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CD27 is detected on normal plasma cells, its expression
is significantly reduced with the progression of multiple
myeloma (MM) [25-29]. MM patients in complete clini-
cal remission displayed a higher percentage of CD27+
PC compared with patients at diagnosis, relapse or in
partial remission [30]. No report has been found for
CD27 expression in EMP yet. In current study, 43.8% of
cases were positive for CD27.
CD44v6 is an isoform of the type 1 transmembrane
glycoprotein CD44 generated by alternative splicing and
has been implicated in cell adhesion and signaling,
growth factor and cytokine presentation, as well as
tumor dissemination [31-35]. Data on the incidence of
CD44v6 in clonal plasma cell disorders are scarce. Lie-
bisch et al [36] had observed CD44v6 expression in a
group of plasma cell disorders, the results showed that
CD44v6 was expressed in 13/32 in stage II/III MM cor-
related with chromosome 13q deletion, 1/6 in stage IA
MM as well as 1/16 in MGUS. Therefore, the authors
believed that CD44v6 is frequently expressed in
advanced, high-risk MM. CD44v6 expression correlates
with chromosomal band 13q14 deletions, a well known
risk factor in MM. Eisterer et al [37] reported that
CD44s was expressed strongly in all plasma cell popula-
tions included normal individuals, MGUS, MM, eMM
and EMP. Although in 49 MMs, CD44v3 and CD44v6
expressed in 7 cases and 6 cases respectively, in 5
eMMs they were expressed in 3 cases and 4 cases
respectively and in 2 EMPs they were expressed in all.
In current series of cases, 56.3% of the cases expressed
CD44v6, slightly higher than that reported in the litera-
ture. No difference of CD56, CD27 and CD44v6
expression was found in both low and high grade of
EMP in current study at all.
The neoplastic cells of EMP and MM are positive for
Bcl-2, whereas the reactive plasma cells usually do not
express Bcl-2. Several authors also observed the rela-
tionship among CD45, Bcl-2 and Ki-67. No critical
result was found now, in this study, nothing new was
found as well.
Acknowledgements
This work was supported in part by grants from the National Natural Science
Foundation of China (N0. 30470747), the Ph.D. Programs Foundation of
Ministry of Education of China (N0. 20070610141) and the Ministry of Health
Industry Research Special Fund funded projects (N0. 200802011).
Author details
1Department of Pathology, West China Hospital of Sichuan University,
Chengdu, China.
2Department of Oncology, West China Hospital of Sichuan
University, Chengdu, China.
Authors’ contributions
ZZ participated in the design, analyses and data interpretation and drafted
the manuscript., YT, CFB, WYZ, SZ, XQW, QPY, LQZ collected pathologic and
clinical information and helped to draft the manuscript. WPL conceived of
the study and participated in its design and analyses and helped to draft
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 October 2011 Accepted: 19 December 2011
Published: 19 December 2011
References
1. SH Swerdlow EC, Harris NL, Jaffe ES, Pileri SA, Thiele J, et al: WHO
classification of tumours of haematopoietic and lymphoid tissues, International
Agency for Research on Cancer (IARC) Lyon, France; 2008.
2. Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spieb JC, Schratzenstaller B,
Arnold W: Extramedullary plasmacytoma. Cancer 1999, 85:2305-2314.
3. Bachar G, Goldstein D, Brown D, Tsang R, Lockwood G, Perez-Ordonez B,
Irish J: Solitary extramedullary plasmacytoma of the head and neck–
Long-term outcome analysis of 68 cases. Head & Neck 2008, 30:1012-1019.
4. Kremer M, Ott G, Nathrath M, Specht K, Stecker K, Alexiou C, Quintanilla-
Martinez L, Fend F: Primary extramedullary plasmacytoma and multiple
myeloma: phenotypic differences revealed by immunohistochemical
analysis. The Journal of Pathology 2005, 205:92-101.
5. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS:
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple
myeloma: incidence and survival in the United States, 1992-2004. British
Journal of Haematology 2009, 144:86-94.
6. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D:
Guidelines on the diagnosis and management of solitary plasmacytoma
of bone and solitary extramedullary plasmacytoma. British Journal of
Haematology 2004, 124:717-726.
7. Bartl RFB, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W:
Histologic classification and staging of multiple myeloma: a
retrospective and prospective study of 674 cases. Am J Clin Pathol 1987,
87:342-355.
8. van Dongen JJM, Langerak AW, Bruggemann M, Evans PAS, Hummel M,
Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, et al: Design
and standardization of PCR primers and protocols for detection of
clonal immunoglobulin and T-cell receptor gene recombinations in
suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action
BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
9. Weber DM: Solitary Bone and Extramedullary Plasmacytoma. Hematology
2005, 2005:373-376.
Table 5 The major phenotypic differences of EMP and
chronic inflammation of nasal and sinonasal regions with
numerous plasma cell (PC) infiltrations
Antibodies EMP
(n = 32)
Chronic inf.
(n = 12)
P value
CD45 34.4% 100% 0.000
CD27 43.8% 100% 0.001
CD44v6 56.3% 0 0.011
Bcl-2 96.9% 0 0.000
Table 6 The major phenotypic differences of EMP and
SPB
Antibodies EMP
(n = 32)
SPB
(n = 21)
P value
CD56 18.7% 57.1% 0.004
EMA 31.3% 81.0% 0.000
CD27 43.8% 15.0% 0.032
CD44v6 56.3% 23.8% 0.020
Zuo et al. Diagnostic Pathology 2011, 6:123
http://www.diagnosticpathology.org/content/6/1/123
Page 10 of 1110. Susnerwala S, Shanks JH, Banerjee SS, Scarffe JH, Farrington WT, Slevin NJ:
Extramedullary plasmacytoma of the head and neck region:
clinicopathological correlation in 25 cases. British Journal of Cancer 1997,
75:921-927.
11. Mendenhall WM, Mendenhall CM, Mendenhall NP: Solitary plasmacytoma
of bone and soft tissues. American Journal of Otolaryngology 2003,
24:395-399.
12. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE: CD45 expression
by bone marrow plasma cells in multiple myeloma: clinical and
biological correlations. Leukemia 2005, 19:1466-1470.
13. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N,
Harousseau J, Bataille R: Patients with CD45 negative multiple myeloma
receiving high-dose therapy have a shorter survival than those with
CD45 positive multiple myeloma. Haematologica 2004, 89:547-551.
14. Van Camp B, Durie B, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y,
Richter L, Grogan T: Plasma cells in multiple myeloma express a natural
killer cell- associated antigen: CD56 (NKH-1; Leu-19). Blood 1990,
76:377-382.
15. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau J, Rapp M, Juge-
Morineau N, Wijdenes J, Amiot M: Expression of CD28 and CD40 in
human myeloma cells: a comparative study with normal plasma cells.
Blood 1994, 84:2597-2603.
16. Pellat-Deceunynck C, Barillé S, Puthier D, Rapp M-J, Harousseau J-L,
Bataille R, Amiot M: Adhesion Molecules on Human Myeloma Cells:
Significant Changes in Expression Related to Malignancy, Tumor
Spreading, and Immortalization. Cancer Research 1995, 55:3647-3653.
17. Kouno T, Watanabe T, Umeda T, Beppu Y, Kojima R, Sungwon K,
Kobayashi Y, Tobinai K, Hasegawa T, Matsuno Y: CD56-positive Small
Round Cell Tumor: Osseous Plasmacytoma Manifested in Osteolytic
Tumors of the Iliac Bone and Femora. Japanese Journal of Clinical
Oncology 2005, 35:90-93.
18. Camerini D, Walz G, Loenen W, Borst J, Seed B: The T cell activation
antigen CD27 is a member of the nerve growth factor/tumor necrosis
factor receptor gene family. The Journal of Immunology 1991,
147:3165-3169.
19. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R,
Tough TW, Schoenborn MA, Davis-Smith T, Hennen K, et al: Molecular and
biological characterization of a ligand for CD27 defines a new family of
cytokines with homology to tumor necrosis factor. Cell 1993, 73:447-456.
20. Maurer D, Holter W, Majdic O, Fischer GF, Knapp W: CD27 expression by a
distinct subpopulation of human B lymphocytes. European Journal of
Immunology 1990, 20:2679-2684.
21. Klein U, Rajewsky K, Küppers R: Human Immunoglobulin (Ig)M+IgD+
Peripheral Blood B Cells Expressing the CD27 Cell Surface Antigen Carry
Somatically Mutated Variable Region Genes: CD27 as a General Marker
for Somatically Mutated (Memory) B Cells. The Journal of Experimental
Medicine 1998, 188:1679-1689.
22. Tangye SG, Liu Y-J, Aversa G, Phillips JH, de Vries JE: Identification of
Functional Human Splenic Memory B Cells by Expression of CD148 and
CD27. The Journal of Experimental Medicine 1998, 188:1691-1703.
23. Lens SMA, Jong RD, Hintzen RQ, Koopman G, Van Lier RAW, Van Oers RHJ:
CD27-CD70 Interaction: Unravelling its Implication in Normal and
Neoplastic B-Cell Growth. Leukemia & Lymphoma 1995, 18:51-59.
24. Agematsu K, Hokibara S, Nagumo H, Komiyama A: CD27: a memory B-cell
marker. Immunology Today 2000, 21:204-206.
25. Farstad IN, Carlsen H, Morton HC, Brandtzaeg P: Immunoglobulin A cell
distribution in the human small intestine: phenotypic and functional
characteristics. Immunology 2000, 101:354-363.
26. Jung J, Choe J, Li L, Choi YS: Regulation of CD27 expression in the course
of germinal center B cell differentiation: the pivotal role of IL-10.
European Journal of Immunology 2000, 30:2437-2443.
27. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R,
Yang Y, Wilson C, Zangari M, et al: Global gene expression profiling of
multiple myeloma, monoclonal gammopathy of undetermined
significance, and normal bone marrow plasma cells. Blood 2002,
99:1745-1757.
28. Katayama Y, Sakai A, Oue N, Asaoku H, Otsuki T, Shiomomura T, Masuda R,
Hino N, Takimoto Y, Imanaka F, et al: A possible role for the loss of CD27-
CD70 interaction in myelomagenesis. British Journal of Haematology 2003,
120:223-234.
29. Moreau P, Robillard N, Jégo G, Pellat C, Gouill SL, Thoumi S, Avet-Loiseau H,
Harousseau J-L, Bataille R: Lack of CD27 in myeloma delineates different
presentation and outcome. British Journal of Haematology 2006,
132:168-170.
30. Guikema JEJ, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH,
Bekkema R, Smit JW, Zhan F, Shaughnessy J, Bos NA: CD27 is
heterogeneously expressed in multiple myeloma: low CD27 expression
in patients with high-risk disease. British Journal of Haematology 2003,
121:36-43.
31. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG: In
vitro culture of primary plasmacytomas requires stromal cell feeder
layers. Proceedings of the National Academy of Sciences 1993, 90:2060-2064.
32. Okada T, Hawley RG: Adhesion molecules involved in the binding of
murine myeloma cells to bone marrow stromal elements. International
Journal of Cancer 1995, 63:823-830.
33. Asosingh K, Günthert U, Bakkus MHC, De Raeve H, Goes E, Van Riet I, Van
Camp B, Vanderkerken K: In Vivo Induction of Insulin-like Growth Factor-I
Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple
Myeloma Cells. Cancer Research 2000, 60:3096-3104.
34. Lokhorst H, Lamme T, de Smet M, Klein S, de Weger R, van Oers R,
Bloem A: Primary tumor cells of myeloma patients induce interleukin-6
secretion in long-term bone marrow cultures. Blood 1994, 84:2269-2277.
35. UG: CD44: a multitude of isoforms with diverse functions. Anglais 1993,
184:47-63.
36. Liebisch P, Eppinger S, Schopflin C, Stehle G, Munzert G, Dohner H,
Schmid M: CD44v6, a target for novel antibody treatment approaches, is
frequently expressed in multiple myeloma and associated with deletion
of chromosome arm 13q. Haematologica 2005, 90:489-493.
37. Eisterer W, Bechter O, Hilbe W, van Driel M, Lokhorst HM, Thaler J,
Bloem AC, Günthert U, Stauder R: CD44 isoforms are differentially
regulated in plasma cell dyscrasias and CD44v9 represents a new
independent prognostic parameter in multiple myeloma. Leukemia
Research 2001, 25:1051-1057.
doi:10.1186/1746-1596-6-123
Cite this article as: Zuo et al.: Extraosseous (extramedullary)
plasmacytomas: a clinicopathologic and immunophenotypic study of 32
Chinese cases. Diagnostic Pathology 2011 6:123.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zuo et al. Diagnostic Pathology 2011, 6:123
http://www.diagnosticpathology.org/content/6/1/123
Page 11 of 11